Supplementary material

TABLE S1 Analyses of ACQ-7 scores with reslizumab by GINA Step 4 baseline therapy

Assessment	Reduction in ACQ-7 scores with reslizumab treatment, median (95% CI)	
	Medium dose ICS/LABA	High dose ICS/LABA
Week 16	–0.293 (–0.423, –0.163)	–0.402 (–0.584, –0.220)
Week 52	–0.314 (–0.445, –0.183)	–0.371 (–0.553, –0.189)

ACQ: asthma control questionnaire; CI: confidence interval.

TABLE S2 Analyses of AQLQ scores with reslizumab by GINA Step 4 baseline therapy

Assessment	Increase in AQLQ scores with reslizumab treatment, median (95% CI)	
	Medium dose ICS/LABA	High dose ICS/LABA
Week 16	0.279 (0.079, 0.479)	0.329 (0.080, 0.579)
Week 52	0.305 (0.134, 0.476)	0.406 (0.185, 0.628)

AQLQ: asthma quality of life questionnaire; CI: confidence interval.